Agenus Inc. (AGEN) Drops 6.49% on January 19

Equities Staff |

Agenus Inc. (AGEN) was one of the Russell 2000's biggest losers for Tuesday January 19 as the stock slid 6.49% to $2.96, a loss of $-0.205 per share. Starting at an opening price of $3.26 a share, the stock traded between $2.90 and $3.30 over the course of the trading day. Volume was 1 million shares over 4,039 trades, against an average daily volume of 1.35 million shares and a total float of 84.65 million.

The losses send Agenus Inc. down to a market cap of $250.13 million. In the last year, Agenus Inc. has traded between $10.16 and $3.02, and its 50-day SMA is currently $4.42 and 200-day SMA is $6.35.

Agenus Inc along with its subsidiaries is a biopharmaceutical company. The Company is engaged in developing and commercializing technologies to treat cancers and degenerative disorders.

Agenus Inc. is based out of Lexington, MA and has some 175 employees. Its CEO is Garo H Armen.

For a complete fundamental analysis analysis of Agenus Inc., check out’s Stock Valuation Analysis report for AGEN. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets


Lyft matches drivers using their own personal vehicles with passengers who request rides through the smartphone app, and the passengers pay automatically through the app. When using Lyft, passengers have…


The spark hit Jamie when he saw co-workers competing to lose weight. Instead of pizzas and subs, they were eating salads and jogging along the river. Some were sneakily leaving…